Trial Profile
Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs YHD 1023 (Primary) ; Tadalafil
- Indications Erectile dysfunction
- Focus Therapeutic Use
- Sponsors Yuhan
- 30 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2014 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea: KCT0001049)
- 13 May 2013 Planned end date changed from 1 May 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.